|14.05||-0.1600||-1.13%||Vol 1.06M||1Y Perf -12.66%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||-0.07 -0.50%|
|Target Price||19.90||Analyst Rating||Strong Buy 1.40|
|Potential %||41.64||Finscreener Ranking||★★★★+ 56.15|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 58.44|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 84.66|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||26.86||Earnings Rating||Sell|
|Market Cap||1.50B||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.24|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||615.16K|
|Avg. Monthly Volume||1.01M|
|Avg. Quarterly Volume||1.13M|
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.50B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.
The one-year performance of Catalyst Pharmaceuticals Inc. stock is -12.66%, while year-to-date (YTD) performance is -24.46%. CPRX stock has a five-year performance of 453.15%. Its 52-week range is between 11.09 and 22.11, which gives CPRX stock a 52-week price range ratio of 26.86%
Catalyst Pharmaceuticals Inc. currently has a PE ratio of 32.10, a price-to-book (PB) ratio of 7.55, a price-to-sale (PS) ratio of 12.90, a price to cashflow ratio of 22.70, a PEG ratio of -, a ROA of 25.63%, a ROC of 28.06% and a ROE of 30.53%. The company’s profit margin is 37.54%, its EBITDA margin is 44.00%, and its revenue ttm is $153.45 Million , which makes it $1.47 revenue per share.
Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $19.9, which is +41.64% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalyst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.28, ATR14 : 0.52, CCI20 : 104.68, Chaikin Money Flow : 0.08, MACD : 0.36, Money Flow Index : 77.66, ROC : 14.04, RSI : 60.88, STOCH (14,3) : 81.65, STOCH RSI : 0.42, UO : 52.98, Williams %R : -18.35), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $135 500), Alicia Grande (Sold 110 000 shares of value $1 822 313 ), Brian Elsbernd (Option Excercise at a value of $56 500), Brian Elsbernd (Sold 50 000 shares of value $803 450 ), Carmen Jeffrey Del (Sold 0 shares of value $-127 063 ), Carmen Jeffrey Del (Sold 40 000 shares of value $667 810 ), Charles B. O'Keeffe (Option Excercise at a value of $79 000), David S. Tierney (Option Excercise at a value of $39 500), David S. Tierney (Sold 30 000 shares of value $504 900 ), Denkhaus Donald (Sold 0 shares of value $-107 300 ), Donald A. Denkhaus (Option Excercise at a value of $39 500), Elsbernd Brian (Sold 0 shares of value $-56 500 ), Elsbernd Brian (Sold 50 000 shares of value $803 500 ), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 5 918 shares of value $99 718 ), Grande Alicia (Option Excercise at a value of $135 500), Grande Alicia (Sold 110 000 shares of value $1 822 313 ), Harper Molly (Option Excercise at a value of $0), Ingenito Gary (Option Excercise at a value of $0), Molly Harper (Option Excercise at a value of $0), Patrick J. McEnany (Option Excercise at a value of $158 000), Patrick J. Mcenany (Sold 26 151 shares of value $345 978 ), Philip H. Coelho (Option Excercise at a value of $0), Preethi Sundaram (Option Excercise at a value of $0), Richard J. Daly (Option Excercise at a value of $0), Steve Miller (Sold 0 shares of value $-79 000 ), Steven R. Miller (Option Excercise at a value of $0), Sundaram Preethi (Option Excercise at a value of $0)
Mon, 14 Aug 2023 12:48 GMT Catalyst Pharmaceuticals announces multiple abstracts on FYCOMPA- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.